Infectious and sterile endophthalmitis after intravitreal injections: differential diagnosis, prevention, treatment

Cover Page

Cite item

Full Text

Abstract

Endophthalmitis is a rare but extremely severe complication of different intraocular procedures. In the article, we analyze world literature data on prevalence, differential diagnosis, prevention methods, and treatment of endophthalmitis after intravitreal injections.

About the authors

Yury S Astakhov

FSBEI HE “Academician I.P. Pavlov First St Petersburg State Medical University” of the Ministry of Healthcare of Russia

Author for correspondence.
Email: astakhov73@mail.ru

MD, DMedSc, professor. Ophthalmology Department

Russian Federation, Saint Petersburg, Russia

Svetlana G Belekhova

FSBEI HE “Academician I.P. Pavlov First St Petersburg State Medical University” of the Ministry of Healthcare of Russia

Email: beleksv@yandex.ru

MD, assistant. Ophthalmology Department

Russian Federation, Saint Petersburg, Russia

Ekaterina A Litvinova

FSBEI HE “Academician I.P. Pavlov First St Petersburg State Medical University” of the Ministry of Healthcare of Russia

Email: evgenica159@mail.ru

resident. Ophthalmology Department

Russian Federation, Saint Petersburg, Russia

References

  1. Агеева Е.В., Гродненская А.Е., Попова К.А. Роль профилактического назначения местных антибактериальных препаратов перед интравитреальной инъекцией // Офтальмологические ведомости. – 2015. – Т. 8. – № 2. – С. 80–83. [Ageeva EV, Grodnenskaya AE, Popova KA. Therole of preventive topical antibiotic treatment prior to intravitreal injection. Oftal’mologicheskie vedomosti. 2015;8(2)80-83. (In Russ.)]
  2. Астахов С.Ю., Вохмяков A.B. Эндофтальмит: профилактика, диагностика, лечение // Офтальмологические ведомости. – 2008. – Т. 1. – № 1. – С. 35–45. [Astakhov SYu, Vokhmyakov AB. Endoftal’mit: profilaktika, diagnostika, lechenie. Oftal’mologicheskie vedomosti. 2008;1(1):35-45. (In Russ.)]
  3. Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal Anti-VEGF pharmacotherapy. Hindawi Publishing Corporation Mediators of Inflammation. 2013; ArticleID943409, 6 pages doi: 10.1155/2013/943409.
  4. Ang GS, Varga Z, Shaarawy. Postoperative infection in penetrating versus non-penetrating glaucoma surgery. Br J Ophthalmol. 2010;94:1571-76. doi: 10.1136/bjo.2009.163923.
  5. Barry P, Cordovés L, Gardner S. ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions. Ireland, The European Society of Cataract and Refractive Surgeons; 2013.
  6. Casparis H, Wolfensberger TJ, Becker M, et al. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study. Retina. 2014;34(1):12-7. doi: 10.1097/IAE.0b013e31829f74b0.
  7. Cheung CS, Wong AW, Lam WС. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119:1609-14. doi: 10.1016/j.ophtha.2012.02.014.
  8. Chong DY, Anand R, Williams PD, et al. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina. 2010;30(9):1432-40. doi: 10.1097/IAE.0b013e3181dc04da.
  9. Cohen SM, Flynn Jr HW, Murray TG, Smiddy WE. Endophthalmitis after pars plana vitrectomy. The Postvitrectomy Endophthalmitis Study Group. Ophthalmology. 1995;102:705-12. doi: 10.1016/S0161-6420(95)30965-7.
  10. Martin DF, Maguire MG, Fine SL, et al. Comparison of Age-related Macular Degeneration Treatments Trials (CATT), Research. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053.
  11. Cottingham AJ, Forster RK. Vitrectomy in endophthalmitis: result of study using vitrectomy, intraocular antibiotics, or a combination of both. Arch Ophtalmol. 1976;94:2078-81. doi: 10.1001/archopht.1976.03910040738007.
  12. Dave SB, Toma HS, Kim SJ. Changes in ocular flora in eyes exposed to ophthalmic antibiotics. Ophthalmology. 2013;120(5):937-4
  13. Day S, Acquah K, Mruthyunjaya P, et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152:266-72. doi: 10.1016/j.ajo.2011.01.053.
  14. Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33(6):978-88. doi: 10.1016/j.jcrs.2007.02.032.
  15. Eifrig C, Scott I, et al. Аcute-onset postoperative endophthalmitis: Review of incidence and visual outcomes (1995-2001). Ophthalmic Surg Lasers. 2002;33:373-378.
  16. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113:1479-96. doi: 10.1001/archopht.1995.01100120009001
  17. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008;28:1395-9. doi: 10.1097/IAE.0b013e3181884fd2.
  18. Forster RK. Experimental postoperative endophthalmitis. Trans Ophtalmol. 1992;90:505-559.
  19. Friedman DA, et al. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina. 2013;33(5):975-81. doi: 10.1097/IAE.0b013e3182877585.
  20. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-49. doi: 10.1136/bjo.2006.099598.
  21. Georgopoulos M, Polak K, Prager F, et al.. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol. 2009;93(4):457-62. doi: 10.1136/bjo.2008.138479.
  22. Haas W, Pillar CM, Torres M, et al. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol. 2011;152(4):567-74. doi: 10.1016/j.ajo.2011.03.010.
  23. Hahn P. Aflibercept — related sterile inflammation. Ophthalmology. 2013;120(5):1100-101. doi: 10.1016/j.ophtha.2012.11.018.
  24. Hahn P, Chung MM, Flynn HW Jr. Postmarketing Analysis of Aflibercept-Related Sterile Intraocular Inflammation. JAMA Ophthalmol. 2015;133(4):421-426. doi: 10.1001/jamaophthalmol.2014.5650.
  25. Hamill MB, Osato MS, Wilhelmus KR. Experimental evaluation of chlorhexidine gluconate for ocular antisepsis. Antimicrob Agents Chemother. 1984;26(6):793-6. doi: 10.1128/AAC.26.6.793.
  26. Hatch WV, Cernat G, Wong D, et al. Risk factors for acute endophthalmitis after cataract surgery: a population-based study. Ophthalmology. 2009;116:425-30. doi: 10.1016/j.ophtha.2008.09.039.
  27. Heier J, Brown D, Chong V, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology. 2012;119:2537-48. doi: 10.1016/j.ophtha.2012.09.006.
  28. Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. Journal of Interferon and Cytokine Research. 1997;17(1)15-21.
  29. Hoevenaars NED, Gans D, Missotten T, et al. Suspected bacterial endophthalmitis following intravitreal anti-VEGF injection: Case series and literature review. Ophthalmologica. 2012;228:143-47. doi: 10.1159/000339584.
  30. Hsu J, Gerstenblith AT, Garg SJ, Vander JF. Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without postinjection topical antibiotics. Am J Ophthalmol. 2014;157(3):514-8. doi: 10.1016/j.ajo.2013.10.003.
  31. Isenberg SJ, Apt L, Yoshimori R, Khwarg S. Chemical preparation of the eye in ophthalmic surgery. IV. Comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol. 1985;103(9):1340-2. doi: 10.1001/archopht.1985.01050090092039.
  32. Jager R, Aiello L, Patel S, Cunningham E. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676-98. doi: 10.1097/00006982-200410000-00002.
  33. Jager RD, Timothy N, Coney G, et al. Endophthalmitis as a complication of intravitreal injection: a systemic review. Presented at ARVO, Ft. Lauderdale. 2004, abs. 2001.
  34. Jonas JB, Spandau UH, Rensch F, et al. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther. 2007;23:240-2. doi: 10.1089/jop.2006.0146.
  35. Kattan HM, Flynn HW. Nosocomial endophtalmitis survey. Сurrent incidence of infection after intraocular surgery. Ophtalmology. 1991;98:227-38.
  36. Katz LJ, Сantor LB, Spaech GL. Complications of surgery in glaucoma: Early and late bacterial endophthalmitis following glaucoma filtering surgery. Ophthalmology. 1985;92:959-63.
  37. Khan RI, Kennedy S, Barry P. Incidence of presumed postoperative endophthalmitis in Dublin for a 5-year period (1997-2001). J Cataract Refract Surg. 2005;31:1575-81. doi: 10.1016/j.jcrs.2005.01.031.
  38. Koc F, Sen E, Demirbay P, et al. Factors influencing treatment result in pseudophakic endophtalmitis. Eur J Оphtalmol. 2002;12:34-9.
  39. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans — Clinical significance, assessment and prediction. Current Pharmaceutical Biotechnology. 2002;3(4):349-60. doi: 10.2174/1389201023378175.
  40. Kunimoto DY, Kaiser RS, Wills Eye Retina Service. Incidence of endophthalmitis after 20- and 25-gauge vitrectomy. Ophthalmology. 2007;114(12):2133-37. doi: 10.1016/j.ophtha.2007.08.009.
  41. Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: Our experience after 2,000 injections. Retina. 2009;29(3)313-18.
  42. Lemley CA, Han DP. Endophthalmitis: a review of current evaluation and management. Retina. 2007;27(6):662-680. doi: 10.1097/IAE.0b013e3180323f96.
  43. Mason JO. III, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-67. doi: 10.1097/IAE.0b013e3181633fee.
  44. Moshfeghi A, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: A six-year experience at a university referral center. Retina. 2011;31:662-8. doi: 10.1097/IAE.0b013e31821067c4.
  45. Moshirfar M, Feiz V, Vitale AT, et al. Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series. Ophthalmology. 2007;114(4):686-91. doi: 10.1016/j.ophtha.2006.08.038.
  46. Nelson DM. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina. 2003;23(5):686-91. doi: 10.1097/00006982-200310000-00014.
  47. Peyman G, Lee P, Seal DV. Endophthalmitis – diagnosis and management. Taylor & Francis, London. 2004:1-270. doi: 10.3109/9780203017630-2.
  48. Pleyer U, Mondino BJ, Adamu SA, et al. Immune response to Staphylococcus epidermidis endophthalmitis in a rabbit model. Invest Ophthalmol Vis Sci. 1992;33:2650-63.
  49. Ramulu PY, Do DV, Corcoran KJ, et al. Use of retinal procedures in Medicare beneficiaries from 1997 to 2007. Arch Ophthalmol. 2010;128:1335-40. doi: 10.1001/archophthalmol.2010.224.
  50. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145(5):879-82. doi: 10.1016/j.ajo.2007.12.036.
  51. Roth DB, Lee SS, Flynn HW, Jr. Inflammatory reactions after intravitreal triamcinolone acetonide: Possible mechanisms and therapeutic options. Expert Rev Ophthalmol. 2010;5(3):273-76. doi: 10.1586/eop.10.20.
  52. Roth DB, Modi КK, Flynn HW Jr. Distinguishing Infection Post-Intravitreal Injection. Review of Ophthalmology. 2013;20(7):1-42.
  53. Scott IU, Flynn HW Jr, Dev S, et al. Endophthalmitis after 25-gauge and 20-gauge pars plana vitrectomy: incidence and outcomes. Retina. 2008;28:138-42. doi: 10.1097/IAE.0b013e31815e9313.
  54. Shah CP, Garg SJ, Vander JF, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028-34. doi: 10.1016/j.ophtha.2011.02.034.
  55. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008;86:372-6. doi: 10.1111/j.1600-0420.2007.01067.x.
  56. Somani S, Grinbaum A, Slomovic AR. Post-operative endophthalmitis: incidence, predisposing surgery, clinical course and outcome. Can J Ophthalmol. 1997;32:303-10.
  57. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 1991;98:1769-75. doi: 10.1016/S0161-6420(91)32052-9.
  58. Stepien KE, Eaton AM, Jaffe GJ, et al. Increased incidence of sterile endophthalmitis after intravitreal triamcinolone acetonide in Spring 2006. Retina. 2009;29:207-13. doi: 10.1097/IAE.0b013e31818eccb3.
  59. Storey P, Dollin M, Pitcher J, et al. Post-Injection Endophthalmitis Study T. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014;121(1):283-9. doi: 10.1016/j.ophtha.2013.08.037.
  60. Taban M, Behrens A, Newcomb RL, et al. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol. 2005;123(5):613-20. doi: 10.1001/archopht.123.5.613.
  61. Taban M, Singh RP, Chung JY, et al. Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis. Am J Ophthalmol. 2007;144:50-4. doi: 10.1016/j.ajo.2007.03.051.
  62. Talley AR, D, Amico DJ, Talamo JH. The role of vitrectomy in the treatment of the postoperative endophthalmitis: of a experimental study. Arch Ophtalmol. 1987;105:1699-1702. doi: 10.1001/archopht.1987.01060120097034.
  63. Whitacre MM, Crockett RS. Tolerance of intravitreal povidone-iodine in rabbit eyes. Curr Eye Res. 1990;9(8):725-32. doi: 10.3109/02713689008999567.
  64. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 2008;115(11):1911-15. doi: 10.1016/j.ophtha.2008.05.007.
  65. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe’s Arch Clin Exp Ophthalmol. 2008;46:81-7.
  66. Wykoff C, Flynn H Jr, Rosenfeld P. Prophylaxis for endophthalmitis following intravitreal injection: antisepsis and antibiotics. Am J Ophthalmol. 2011;155(5):717-9. doi: 10.1016/j.ajo.2011.07.002.
  67. Yamashiro K, Tsujikawa A, Miyamoto K, et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina. 2010;30(3):485-90. doi: 10.1097/IAE.0b013e3181bd2d51.

Copyright (c) 2017 Astakhov Y.S., Belekhova S.G., Litvinova E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies